Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Media Release: Health Action International Comments on WHO Decision on Analogue Insulin
In July 2019, we supported the announcement that long-acting analogue insulins would not be added to the World Health Organization (WHO) Model List of the Essential Medicines (EML) | Download the Press Release
Media Release: Access a Major Obstacle for One in Two People Using Insulin to Manage Type 2 Diabetes
A paper published in The Lancet Diabetes and Endocrinology estimates that, between 2018 and 2030, the number of people with type 2 diabetes using insulin will rise to 79 million. But without improved availability and affordability, over half of those will face challenges in accessing this life-saving medicine | Download the Press Release
Media Release: Shocking Disparity Between Insulin Prices and Cost of Production
A study published on Tuesday 25 September, 2018 in BMJ Global Health shows that, in a global market dominated by just three multinational companies, people living with diabetes are paying far more than they should for life-saving insulin. | Download the Press Release
Media Release: Health Action International Commend Decision By World Health Organization Not To Include Long-Acting Analogue Insulins On The Essential Medicines List
Press Release | 6 June, 2017 | Download PDF
Statement to the 21st meeting of the WHO Expert Committee on Selection and Use of Essential Medicines
Presented by Dr. Marg Ewen on 27 March 2017 | Click here to download the full statement.
Comment from Health Action International to Expert Committee on the application to include long-acting analogue insulins in the WHO Model List of Essential Medicines
Submission to the Expert Committee from HAI
Insulin discounts lower price burden for Americans, but insulin still not affordable worldwide
AMSTERDAM— Researchers conducting a global study into the barriers to insulin access call on Eli Lilly, Novo Nordisk and Sanofi to lower prices for all types of insulin worldwide and for greater transparency of actual prices paid for insulin. Read more
ACCISS Study Reveals Numerous Barriers Hindering Access to Insulin for Millions in Need
GENEVA—A number of barriers are impeding access to insulin around the world, according to new research published today by Health Action International, Geneva University Hospitals/University of Geneva and Boston University School of Public Health. Read more
Listen: ACCISS Study Investigator, David Beran, Speaks to The Lancet D&E About Insulin Access
Coinciding with the release of the ACCISS Study’s new Review, ‘Constraints and Challenges in Access to Insulin: A Global Perspective‘, in The Lancet Diabetes & Endocrinology, co-author David Beran spoke with the journal about key issues affecting access to insulin. Read more
Innovative Global Study Launched to Improve Access to Insulin
AMSTERDAM—Health Action International (HAI) has launched an innovative global study, called Addressing the Challenges and Constraints of Insulin Sources and Supply (ACCISS), to identify the causes of poor availability and high insulin prices and develop policies and interventions to improve access to this life-saving medicine, particularly in the world’s most under-served regions. Read more
Media Coverage
Insulin shortage could affect 40 million people with type 2 diabetes
The Guardian – November 21, 2018
Insulin costs NHS five times more than it should
The Times of London – September 25, 2018
Insulin prices could be much lower and drug makers still make healthy profits
STAT News – September 26, 2018
Citing cost, WHO rejects request to add some insulins to essential medicines list
STAT News – June 6, 2017
Long-acting insulin price concerns challenge WHO proposal
InPharma Technologist – May 30, 2017
La fulgurante progression du diabète en Afrique – featuring David Beran
RTS – Radio – April 6, 2017
Diabetics largely depend on foreign made insulin
DNA – November 14, 2016
Access to Insulin in India Constrained by Costs, Lack of Market Competition
Boston University – October 14, 2016
Insulin’s Surging Price Turns Diabetes Staple Into Luxury Good
Bloomberg – April 7, 2016
Barriers hindering access to insulin for millions in need; Report
The Pharmaletter – April 7, 2016
Diabète: les oubliés de l’insuline
Tribune de Geneve – March 4, 2016
Insulin access remains limited for thousands of people, study finds
Diabetes.co.uk – February 8, 2016
Call for Action to Improve Global Access to Insulin
Medscape – February 08, 2016
Insulin Out of Reach for Millions Around the Globe
Medpage Today – February 6, 2016
Life-Saving Insulin Too Costly for Many of the World’s Type 1 Diabetics, Lancet Review Finds
AJMC.com Managed Markets Network – February 06, 2016